Corindus Vascular Robotics Inc

Corindus Vascular Robotics — Investor Presentation (November 2015)

28 slides from Corindus Vascular Robotics's investor presentation, Nov 17, 2015

  1. Slide 1: Precision Vascular Robotics Corindus Vascular Robotics (CVRS) Overview

    Precision Vascular Robotics Corindus Vascular Robotics (CVRS) Overview November 2015 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS THIS PRESENTATION CONTAINS “FORWARD-LOOKING STATEMENTS” (AS SUCH TERM IS DEFINED IN SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND INFORMATION RELATING TO THE COMPANY, THAT ARE BASED ON THE CUR

  3. Slide 3: CorPath System: Only FDA cleared robotic-assisted PCI system

    CorPath® System: Only FDA cleared robotic-assisted percutaneous coronary intervention (“PCI”) system PCI is a high volume, (~933k), US medical robotics procedure opportunity; long growth runway Cath Lab occupational hazards concerns and awareness are growing CorPath precision can leading to better o

  4. Slide 4: Strong Leadership Team

    Strong Leadership Team Experience in the cardiovascular field David Handler President & CEO David Long VP Finance, CFO Gary Lickovitch VP Sales & Service Management

  5. Slide 5: CorPath Robotic PCI Cath Lab Procedure Innovation

    CorPath Robotic PCI Cath Lab Procedure Innovation CorPath® Robotic-assisted PCI 1986 First Stent Procedure Today Procedure Unchanged >> Critical unmet interventional procedure challenges Innovation historically focused on stents and delivery systems Traditional PCI not optimized to required levels o

  6. Slide 6: Vascular Robotics Market

    Vascular Robotics Market CorPath platform potential to expand vascular indications Peripheral (1.5M Procedures) Corindus IP and Technology Neuro Coronary Peripheral Structural

  7. Slide 7: Corindus Market Opportunity

    Corindus Market Opportunity $4.5B FY2018 market estimate2 New System Sales annual market opportunity based on 5-year replacement cycle in 5,430 US labs and 8,150 OUS labs, at a blended average price per system of $350,000. Prices vary by procedure type and geography. Non-PCI procedure types are Peri

  8. Slide 8: Product Overview

    Product Overview Corindus Vascular Robotics

  9. Slide 9: CorPath Robotic-Assisted PCI System

    CorPath Robotic-Assisted PCI System

  10. Slide 10: Simple to Install and Easy to Learn

    Simple to Install and Easy to Learn CorPath Installation The CorPath system fits in any cath lab and is compatible with all fluoroscopy systems; Philips, GE, Siemens, Toshiba. No construction is required. Several electronic cables are used to connect the bedside with the cockpit for robotics and ima

  11. Slide 11: Today's Cath Lab Challenges

    Today’s Cath Lab Challenges Staff Safety and Health is at Risk The cath lab is a dangerous environment for workers Radiation exposure à cancer and cataract risk Ergonomic Strain à orthopedic injury and chronic pain Procedure Outcomes Not Optimal Difficulty viewing angiography standing at bedside Inc

  12. Slide 12: Safety in a Hazardous Environment

    Lab ergonomics create awkward working positions Lead protection exacerbates stress loading – pressures up to 300 psi on discs propagating “interventionalist disc disease” High radiation exposure – increased risk of brain tumor, leukemia/lymphoma, cataracts Safety in a Hazardous Environment Reduce ra

  13. Slide 13: Escalating Awareness of Risks

    Escalating Awareness of Risks Accelerating publication frequency ORSIF, February 2015 JACC Interventions, April 2015 JACC, March 2015 CCI, April 2015 CCI, February 2015

  14. Slide 14: Occupational Risks in the Cath Lab

    Occupational Risks in the Cath Lab Brain tumors Reported brain tumors are predominately left-side amongst interventionalists1 Orthopedic injuries2,4 60% incidence of spine issues after 21 years in practice 42% incidence of spine problems - General population average rate - 2.3% 33% miss work due to

  15. Slide 15: Traditional PCI vs. CorPath Robotic PCI

    Enhanced procedure may improve outcomes, economics and safety Traditional PCI vs. CorPath® Robotic PCI Struggle to see angiography Assess Anatomy Close proximity ergonomic visualization Trial & error, wire spinning Navigate Precise ‘Point & Shoot’ predictability ‘Eyeball’ estimate Measure Anatomy Ro

  16. Slide 16: Inaccurate lesion assessment

    Inaccurate lesion assessment ~65% physicians select stent length based on visual estimation alone1 51% of physicians underestimated lesion length2 Inaccurate estimate lead to sub-optimal PCI procedure and can cause LGM Longitudinal Geographic Miss (LGM) correlates with higher TVR STLLR trial demonst

  17. Slide 17: PRECISE study compared to historical data

    Nikolsky E, Pucelikova T, Mehran R, et al. An Evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention. J Invasive Cardiol, 2007, 19: 208-213 Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention. J American College of Cardi

  18. Slide 18: Clinical Evidence – Precision Matters

    Clinical Evidence – Precision Matters Peer reviewed publication highlights Continued Investment in Clinical Data Post PRECISE sub-analysis PRECISION registry post market data collection and analysis vs. manual procedures Concurrent studies to prove procedure benefits of CorPath robotic precision vs.

  19. Slide 19: Commercial Strategy

    Commercial Strategy Corindus Vascular Robotics

  20. Slide 20: Sales Strategy

    Sales Strategy Increasing field team to 20 in 2015 System Sales Team Experienced vascular interventional sales professionals – System ‘hunters’ Sales process initiates with Interventional Cardiologist champion, then progresses through hospital administration Leveraging both capital purchase and util

  21. Slide 21: Focused on Strategic Placements

    Focused on Strategic Placements Targeting high-volume, influential IC centers Driving awareness We are in the early stages of our goal to change the paradigm of how PCI procedures are performed Engaging key opinion leaders is integral to building awareness and driving expansion of our platform Mayo

  22. Slide 22: Intellectual Property

    = Intellectual Property Corindus Vascular Robotics

  23. Slide 23: Intellectual Property Overview

    Intellectual Property Overview Expanding on a strong foundation Continuous “Ring-fencing” all vascular robotics applications: 40 issued global patents 53 patents pending: broad application coverage Continuously building IP portfolio Pursuing the vascular space broadly Corindus IP covers remote contr

  24. Slide 24: Financials

    Financials Corindus Vascular Robotics

  25. Slide 25: Key Financial Information

    Key Financial Information Key Metrics* Cash, Cash Equivalents and Marketable Securities$50.3 million Debt** $9.0 million Basic Shares Outstanding118,559,200 Warrants Outstanding 5,207,379 Stock Options Outstanding 8,078,961 * As of September 30, 2015 ** Outstanding principal balance

  26. Slide 26: Corindus Vascular Robotics

    Corindus Vascular Robotics

  27. Slide 27: CorPath System: Only FDA cleared robotic-assisted PCI system

    CorPath® System: Only FDA cleared robotic-assisted percutaneous coronary intervention (“PCI”) system\ Cath Lab occupational hazards concerns and awareness are growing $4.5B market opportunity; long growth runway Growing CorPath strategic installed base for commercial foundation and regional show sit

  28. Slide 28: The New Standard of Care in Vascular Procedures

    Precision Vascular Robotics The New Standard of Care in Vascular Procedures About Corindus Vascular Robotics Corindus Vascular Robotics is a global technology leader in robotic-assisted percutaneous coronary interventions. The company’s CorPath System is the first medical device that offers interven

Corindus Vascular Robotics — Investor Presentation (November 2015) on 6ix